A research released in JAMA Network Open emphasizes the discrepancy among what it costs to supply copyright as well as the retail selling prices patients face. Despite the small output fees, Novo Nordisk hasn't publicly disclosed distinct figures for copyright or its other products, Wegovy.This led Novo Nordisk to carry out even further exploration